Enhancement of DNA vaccine potency by antigen linkage to IFN-Iγ-inducible protein-10

International Journal of Cancer

Volumn 128, Issue 3, 2011, Pages 702-714

  Kang, Tae Heung ^a   Kim, Keon Woo ^a   Bae, Hyun Cheol ^a   Seong, Seung Yong ^b   Kim, Tae Woo ^a,c  

^a Korea University College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Sookmyung Women's University   (South Korea)

Author keywords

CD4+ Th1 T cells; CD8+ T cells; chemokines; DNA vaccines; HPV 16 E7; IP 10

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN E7;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG POTENCY; EMBRYO; ENDOPLASMIC RETICULUM; FEMALE; HUMAN; HUMAN CELL; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; TH1 CELL; WILD TYPE;

ANIMALS; ANTIBODY-DEPENDENT ENHANCEMENT; BASE SEQUENCE; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DENDRITIC CELLS; DNA PRIMERS; GENE AMPLIFICATION; HUMANS; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; NEOPLASMS; POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; TRANSFECTION; VACCINES, DNA;

EID: 78649849528     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25391     Document Type: Article

References (30)

1. Pardoll DM, Beckerleg AM,. Exposing the immunology of naked DNA vaccines. Immunity 1995; 3: 165-9.
2. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA,. DNA vaccines. Annu Rev Immunol 1997; 15: 617-48.
3. Robinson HL, Torres CA,. DNA vaccines. Semin Immunol 1997; 9: 271-83.
4. + T-cells after gene gun immunization. J Exp Med 1998; 188: 1075-82.
5. Hung CF, Cheng WF, Chai CY, Hsu KF, He L, Ling M, Wu TC,. Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J Immunol 2001; 166: 5733-40.
6. Hung CF, He L, Juang J, Lin TJ, Ling M, Wu TC,. Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen. J Virol 2002; 76: 2676-82.
7. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M, Wu TC,. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 2001; 108: 669-78.
8. Hsieh CJ, Kim TW, Hung CF, Juang J, Moniz M, Boyd DA, He L, Chen PJ, Chen CH, Wu TC,. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine 2004; 22: 3993-4001. (Pubitemid 39208763)
9. + T-cells. J Immunol 2002; 168: 2225-32.
10. Nishimura M, Umehara H, Nakayama T, Yoneda O, Hieshima K, Kakizaki M, Dohmae N, Yoshie O, Imai T,. Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J Immunol 2002; 168: 6173-80.
11. Moser B, Loetscher P,. Lymphocyte traffic control by chemokines. Nat Immunol 2001; 2: 123-8.
12. Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD,. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 2002; 168: 3195-204.
13. Christensen JE, de Lemos C, Moos T, Christensen JP, Thomsen AR,. CXCL10 is the key ligand for CXCR3 on CD8+ effector T-cells involved in immune surveillance of the lymphocytic choriomeningitis virus-infected central nervous system. J Immunol 2006; 176: 4235-43.
14. Kang TH, Bae HC, Kim S-H, Seo SH, Son SW, Choi EY, Seong S-Y, Kim TW,. Modification of dendritic cells with IP-10 gene to enhance vaccine potency. J Gene Med, 2009; 11: 889-98.
15. Hirsch C, Gauss R, Horn SC, Neuber O, Sommer T,. The ubiquitylation machinery of the endoplasmic reticulum. Nature 2009; 458: 453-60.
16. Zhang Y, Williams DB,. Assembly of MHC class I molecules within the endoplasmic reticulum. Immunol Res 2006; 35: 151-62.
17. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC,. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56: 21-6.
18. Shen Z, Reznikoff G, Dranoff G, Rock KL,. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 1997; 158: 2723-30.
19. Kang TH, Lee JH, Noh KH, Han HD, Shin BC, Choi EY, Peng S, Hung CF, Wu TC, Kim TW,. Enhancing dendritic cell vaccine potency by combining a BAK/BAX siRNA-mediated antiapoptotic strategy to prolong dendritic cell life with an intracellular strategy to target antigen to lysosomal compartments. Int J Cancer 2007; 120: 1696-703.
20. Kang TH, Lee JH, Bae HC, Noh KH, Kim JH, Song CK, Shin BC, Hung CF, Wu TC, Park JS, Kim TW,. Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments. Immunol Lett 2006; 106: 126-34.
21. Hung CF, Cheng WF, Hsu KF, Chai CY, He L, Ling M, Wu TC,. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 2001; 61: 3698-703.
22. Park YS, Lee JH, Hung CF, Wu TC, Kim TW,. Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant. Infect Immun 2008; 76: 1952-9.
23. Chen CH, Wang TL, Hung CF, Yang Y, Young RA, Pardoll DM, Wu TC,. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000; 60: 1035-42.
24. Kim TW, Hung CF, Ling M, Juang J, He L, Hardwick JM, Kumar S, Wu TC,. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest 2003; 112: 109-17.
25. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, ter Schegget J, Melief CJ, Kast WM,. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23: 2242-9.
26. Tindle RW, Fernando GJ, Sterling JC, Frazer IH,. A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc Natl Acad Sci USA 1991; 88: 5887-91.
27. Kim TW, Hung CF, Boyd D, Juang J, He L, Kim JW, Hardwick JM, Wu TC,. Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol 2003; 171: 2970-6.
28. Bins AD, Jorritsma A, Wolkers MC, Hung CF, Wu TC, Schumacher TN, Haanen JB,. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med 2005; 11: 899-904.
29. Cheng WF, Hung CF, Chen CA, Lee CN, Su YN, Chai CY, Boyd DA, Hsieh CY, Wu TC,. Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis. Vaccine 2005; 23: 3864-74.
30. Sant AJ,. Endogenous antigen presentation by MHC class II molecules. Immunol Res 1994; 13: 253-67.